Intensity Therapeutics (INTS) Projected to Announce Quarterly Earnings on Thursday

Intensity Therapeutics (NASDAQ:INTS) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Intensity Therapeutics to post earnings of ($0.8725) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. On average, analysts expect Intensity Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Intensity Therapeutics Trading Down 1.1%

Shares of Intensity Therapeutics stock opened at $4.21 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $4.26 and a 200-day simple moving average of $5.85. The stock has a market cap of $11.38 million, a price-to-earnings ratio of -0.74 and a beta of 2.76. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50.

Analyst Upgrades and Downgrades

Several research firms have issued reports on INTS. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Tuesday, July 21st. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intensity Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after purchasing an additional 201,357 shares during the period. State Street Corp increased its position in Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the period. Corient Private Wealth LLC purchased a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $41,000. Finally, Jane Street Group LLC purchased a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $26,000. 3.74% of the stock is currently owned by institutional investors and hedge funds.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.